CN106279136A - 治疗中枢神经***退行性疾病或脑肿瘤的化合物及其应用 - Google Patents
治疗中枢神经***退行性疾病或脑肿瘤的化合物及其应用 Download PDFInfo
- Publication number
- CN106279136A CN106279136A CN201610667749.0A CN201610667749A CN106279136A CN 106279136 A CN106279136 A CN 106279136A CN 201610667749 A CN201610667749 A CN 201610667749A CN 106279136 A CN106279136 A CN 106279136A
- Authority
- CN
- China
- Prior art keywords
- compound
- degenerative disease
- application
- cerebral tumor
- dcm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 58
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 17
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 title claims abstract description 14
- 101000864800 Homo sapiens Serine/threonine-protein kinase Sgk1 Proteins 0.000 claims abstract description 26
- 102100030070 Serine/threonine-protein kinase Sgk1 Human genes 0.000 claims abstract description 26
- 230000003064 anti-oxidating effect Effects 0.000 claims abstract description 7
- 239000003112 inhibitor Substances 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 8
- 206010018338 Glioma Diseases 0.000 claims description 6
- 208000032612 Glial tumor Diseases 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 239000002552 dosage form Substances 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 55
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 29
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 22
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 19
- 208000035126 Facies Diseases 0.000 description 17
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- 239000007832 Na2SO4 Substances 0.000 description 16
- 239000008346 aqueous phase Substances 0.000 description 16
- 229910052938 sodium sulfate Inorganic materials 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 238000005160 1H NMR spectroscopy Methods 0.000 description 14
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 238000005406 washing Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 13
- 238000010898 silica gel chromatography Methods 0.000 description 13
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 235000019136 lipoic acid Nutrition 0.000 description 12
- 229960002663 thioctic acid Drugs 0.000 description 12
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 11
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 239000002027 dichloromethane extract Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 108091000080 Phosphotransferase Proteins 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 102000020233 phosphotransferase Human genes 0.000 description 9
- -1 serum Substances 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 229910052717 sulfur Inorganic materials 0.000 description 8
- 239000011593 sulfur Substances 0.000 description 8
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
- 230000008499 blood brain barrier function Effects 0.000 description 7
- 210000001218 blood-brain barrier Anatomy 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000012453 solvate Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 238000012925 biological evaluation Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003862 glucocorticoid Substances 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000004770 neurodegeneration Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- DTVYNUOOZIKEEX-UHFFFAOYSA-N 5-aminoisoquinoline Chemical compound N1=CC=C2C(N)=CC=CC2=C1 DTVYNUOOZIKEEX-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 4
- 101001120056 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit alpha Proteins 0.000 description 4
- 241001597008 Nomeidae Species 0.000 description 4
- 102100026169 Phosphatidylinositol 3-kinase regulatory subunit alpha Human genes 0.000 description 4
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229930195712 glutamate Natural products 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 3
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 3
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 102100021738 Beta-adrenergic receptor kinase 1 Human genes 0.000 description 2
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 2
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 2
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 102000001267 GSK3 Human genes 0.000 description 2
- 108060006662 GSK3 Proteins 0.000 description 2
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 2
- 102100032822 Homeodomain-interacting protein kinase 1 Human genes 0.000 description 2
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 2
- 101000751445 Homo sapiens Beta-adrenergic receptor kinase 1 Proteins 0.000 description 2
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 2
- 101001066404 Homo sapiens Homeodomain-interacting protein kinase 1 Proteins 0.000 description 2
- 101001018978 Homo sapiens MAP kinase-interacting serine/threonine-protein kinase 2 Proteins 0.000 description 2
- 101001106413 Homo sapiens Macrophage-stimulating protein receptor Proteins 0.000 description 2
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 2
- 101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 description 2
- 101001018145 Homo sapiens Mitogen-activated protein kinase kinase kinase 3 Proteins 0.000 description 2
- 101001018196 Homo sapiens Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 description 2
- 101001055085 Homo sapiens Mitogen-activated protein kinase kinase kinase 9 Proteins 0.000 description 2
- 101001059984 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 4 Proteins 0.000 description 2
- 101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 description 2
- 101000945090 Homo sapiens Ribosomal protein S6 kinase alpha-3 Proteins 0.000 description 2
- 101000945093 Homo sapiens Ribosomal protein S6 kinase alpha-4 Proteins 0.000 description 2
- 101001129076 Homo sapiens Serine/threonine-protein kinase N1 Proteins 0.000 description 2
- 101000838578 Homo sapiens Serine/threonine-protein kinase TAO2 Proteins 0.000 description 2
- 101000772231 Homo sapiens Testis-specific serine/threonine-protein kinase 1 Proteins 0.000 description 2
- 101000606129 Homo sapiens Tyrosine-protein kinase receptor TYRO3 Proteins 0.000 description 2
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 2
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000012825 JNK inhibitor Substances 0.000 description 2
- 229940118135 JNK inhibitor Drugs 0.000 description 2
- 102100033610 MAP kinase-interacting serine/threonine-protein kinase 2 Human genes 0.000 description 2
- 102100021435 Macrophage-stimulating protein receptor Human genes 0.000 description 2
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 2
- 102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 description 2
- 102100033058 Mitogen-activated protein kinase kinase kinase 2 Human genes 0.000 description 2
- 102100033059 Mitogen-activated protein kinase kinase kinase 3 Human genes 0.000 description 2
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 description 2
- 102100026909 Mitogen-activated protein kinase kinase kinase 9 Human genes 0.000 description 2
- 102100028194 Mitogen-activated protein kinase kinase kinase kinase 4 Human genes 0.000 description 2
- 102100029166 NT-3 growth factor receptor Human genes 0.000 description 2
- PKCAXJAENGTJFK-UHFFFAOYSA-N Nc1ccncc1.OC(=O)C(F)(F)F Chemical compound Nc1ccncc1.OC(=O)C(F)(F)F PKCAXJAENGTJFK-UHFFFAOYSA-N 0.000 description 2
- 102100025058 Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha Human genes 0.000 description 2
- 101710143448 Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 108091008611 Protein Kinase B Proteins 0.000 description 2
- 102100024924 Protein kinase C alpha type Human genes 0.000 description 2
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 2
- 101710113459 RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 2
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 description 2
- 102100033643 Ribosomal protein S6 kinase alpha-3 Human genes 0.000 description 2
- 102100033644 Ribosomal protein S6 kinase alpha-4 Human genes 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 102100031206 Serine/threonine-protein kinase N1 Human genes 0.000 description 2
- 102100028949 Serine/threonine-protein kinase TAO2 Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102100029350 Testis-specific serine/threonine-protein kinase 1 Human genes 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102100039127 Tyrosine-protein kinase receptor TYRO3 Human genes 0.000 description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- MUKYLHIZBOASDM-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid 2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound NC(=N)N(C)CC(O)=O.OCC(O)C(O)C(O)C(O)C(O)=O MUKYLHIZBOASDM-UHFFFAOYSA-N 0.000 description 1
- KIWODJBCHRADND-UHFFFAOYSA-N 3-anilino-4-[1-[3-(1-imidazolyl)propyl]-3-indolyl]pyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2C3=CC=CC=C3N(CCCN3C=NC=C3)C=2)=C1NC1=CC=CC=C1 KIWODJBCHRADND-UHFFFAOYSA-N 0.000 description 1
- ZJDBQMWMDZEONW-UHFFFAOYSA-N 4-[(2-methylpropan-2-yl)oxycarbonylamino]benzoic acid Chemical compound CC(C)(C)OC(=O)NC1=CC=C(C(O)=O)C=C1 ZJDBQMWMDZEONW-UHFFFAOYSA-N 0.000 description 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 101100028391 Arabidopsis thaliana PI4KB1 gene Proteins 0.000 description 1
- 102100026630 Aurora kinase C Human genes 0.000 description 1
- 108010014380 Autophagy-Related Protein-1 Homolog Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102100037402 Casein kinase I isoform delta Human genes 0.000 description 1
- 102100037398 Casein kinase I isoform epsilon Human genes 0.000 description 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 102000002427 Cyclin B Human genes 0.000 description 1
- 108010068150 Cyclin B Proteins 0.000 description 1
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 1
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 102100028554 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102100023685 G protein-coupled receptor kinase 5 Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 101000765862 Homo sapiens Aurora kinase C Proteins 0.000 description 1
- 101001026336 Homo sapiens Casein kinase I isoform delta Proteins 0.000 description 1
- 101001026376 Homo sapiens Casein kinase I isoform epsilon Proteins 0.000 description 1
- 101000838016 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1A Proteins 0.000 description 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 1
- 101000829476 Homo sapiens G protein-coupled receptor kinase 5 Proteins 0.000 description 1
- 101001043764 Homo sapiens Inhibitor of nuclear factor kappa-B kinase subunit alpha Proteins 0.000 description 1
- 101000956807 Homo sapiens Leukocyte tyrosine kinase receptor Proteins 0.000 description 1
- 101001018141 Homo sapiens Mitogen-activated protein kinase kinase kinase 2 Proteins 0.000 description 1
- 101001055092 Homo sapiens Mitogen-activated protein kinase kinase kinase 7 Proteins 0.000 description 1
- 101000605630 Homo sapiens Phosphatidylinositol 3-kinase catalytic subunit type 3 Proteins 0.000 description 1
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 1
- 101000595746 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Proteins 0.000 description 1
- 101000595751 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 description 1
- 101001126783 Homo sapiens Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform Proteins 0.000 description 1
- 101000610537 Homo sapiens Prokineticin-1 Proteins 0.000 description 1
- 101001051777 Homo sapiens Protein kinase C alpha type Proteins 0.000 description 1
- 101001051767 Homo sapiens Protein kinase C beta type Proteins 0.000 description 1
- 101000971400 Homo sapiens Protein kinase C eta type Proteins 0.000 description 1
- 101000971404 Homo sapiens Protein kinase C iota type Proteins 0.000 description 1
- 101000606502 Homo sapiens Protein-tyrosine kinase 6 Proteins 0.000 description 1
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 description 1
- 101000601460 Homo sapiens Serine/threonine-protein kinase Nek4 Proteins 0.000 description 1
- 101000588540 Homo sapiens Serine/threonine-protein kinase Nek6 Proteins 0.000 description 1
- 101000588545 Homo sapiens Serine/threonine-protein kinase Nek7 Proteins 0.000 description 1
- 101000983111 Homo sapiens Serine/threonine-protein kinase PAK 6 Proteins 0.000 description 1
- 101000582914 Homo sapiens Serine/threonine-protein kinase PLK4 Proteins 0.000 description 1
- 101000864806 Homo sapiens Serine/threonine-protein kinase Sgk2 Proteins 0.000 description 1
- 101000864831 Homo sapiens Serine/threonine-protein kinase Sgk3 Proteins 0.000 description 1
- 101000665442 Homo sapiens Serine/threonine-protein kinase TBK1 Proteins 0.000 description 1
- 101000607332 Homo sapiens Serine/threonine-protein kinase ULK2 Proteins 0.000 description 1
- 101000770774 Homo sapiens Serine/threonine-protein kinase WNK2 Proteins 0.000 description 1
- 101000742982 Homo sapiens Serine/threonine-protein kinase WNK3 Proteins 0.000 description 1
- 101000637839 Homo sapiens Serine/threonine-protein kinase tousled-like 1 Proteins 0.000 description 1
- 101000674731 Homo sapiens TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 Proteins 0.000 description 1
- 101000587313 Homo sapiens Tyrosine-protein kinase Srms Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108060006678 I-kappa-B kinase Proteins 0.000 description 1
- 102000001284 I-kappa-B kinase Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100021892 Inhibitor of nuclear factor kappa-B kinase subunit alpha Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 229930195714 L-glutamate Natural products 0.000 description 1
- 102100038420 Leukocyte tyrosine kinase receptor Human genes 0.000 description 1
- 108010068342 MAP Kinase Kinase 1 Proteins 0.000 description 1
- 108010075656 MAP Kinase Kinase Kinase 2 Proteins 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 101150117157 MYO3 gene Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 101150117329 NTRK3 gene Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102100038329 Phosphatidylinositol 3-kinase catalytic subunit type 3 Human genes 0.000 description 1
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 1
- 102100036056 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Human genes 0.000 description 1
- 102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 description 1
- 102100030278 Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform Human genes 0.000 description 1
- 102000018967 Platelet-Derived Growth Factor beta Receptor Human genes 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 101710109947 Protein kinase C alpha type Proteins 0.000 description 1
- 102100024923 Protein kinase C beta type Human genes 0.000 description 1
- 102100021556 Protein kinase C eta type Human genes 0.000 description 1
- 102100037314 Protein kinase C gamma type Human genes 0.000 description 1
- 102100021557 Protein kinase C iota type Human genes 0.000 description 1
- 102100039810 Protein-tyrosine kinase 6 Human genes 0.000 description 1
- 101710156940 RAC-beta serine/threonine-protein kinase Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 229940126213 SGK1 inhibitor Drugs 0.000 description 1
- 102100037705 Serine/threonine-protein kinase Nek4 Human genes 0.000 description 1
- 102100031401 Serine/threonine-protein kinase Nek6 Human genes 0.000 description 1
- 102100031400 Serine/threonine-protein kinase Nek7 Human genes 0.000 description 1
- 102100026840 Serine/threonine-protein kinase PAK 6 Human genes 0.000 description 1
- 102100030267 Serine/threonine-protein kinase PLK4 Human genes 0.000 description 1
- 102100030069 Serine/threonine-protein kinase Sgk2 Human genes 0.000 description 1
- 102100038192 Serine/threonine-protein kinase TBK1 Human genes 0.000 description 1
- 102100039988 Serine/threonine-protein kinase ULK1 Human genes 0.000 description 1
- 102100039987 Serine/threonine-protein kinase ULK2 Human genes 0.000 description 1
- 102100029063 Serine/threonine-protein kinase WNK2 Human genes 0.000 description 1
- 102100038115 Serine/threonine-protein kinase WNK3 Human genes 0.000 description 1
- 102100032015 Serine/threonine-protein kinase tousled-like 1 Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 102100021228 TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 Human genes 0.000 description 1
- 241000819233 Tribulus <sea snail> Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102100029654 Tyrosine-protein kinase Srms Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960004979 fampridine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- YFMJTLUPSMCTOQ-UHFFFAOYSA-N isoquinoline-5-sulfonic acid Chemical compound N1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 YFMJTLUPSMCTOQ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000009223 neuronal apoptosis Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N pentanal Chemical compound CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- CXWQAPHDSYDHBR-UHFFFAOYSA-N piperidine-4-carboxamide Chemical compound NC(=O)C1CCNCC1.NC(=O)C1CCNCC1 CXWQAPHDSYDHBR-UHFFFAOYSA-N 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108010027883 protein kinase C eta Proteins 0.000 description 1
- 108010062154 protein kinase C gamma Proteins 0.000 description 1
- 108010008359 protein kinase C lambda Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229940047183 tribulus Drugs 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 108010064892 trkC Receptor Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及治疗中枢***退行性疾病或脑肿瘤的化合物、药物组合物及其应用,该化合物具有式()的结构,这些化合物可作为具有抗氧化作用的SGK1和JNK的双靶点抑制剂,而被制成适当的药物剂型用于中枢神经退行性疾病、脑肿瘤的治疗。式(
Description
技术领域
本发明属于医药领域,涉及治疗中枢神经***退行性疾病或脑肿瘤的化合物、药物组合及其应用。本发明还涉及一系列具有抗氧化作用的SGK1和JNK的双靶点抑制剂的制备方法及其应用,它们可被制成适当的药物剂型用于中枢神经退行性疾病、脑肿瘤的治疗。
背景技术
血清和糖皮质激素调节蛋白激酶1(Serum and Glucocorticoid-InducibleKinase1,SGK1)是1993年Webster等通过糖皮质激素诱导转录大鼠乳腺癌细胞的表达差异筛选发现的一种丝/苏氨酸蛋白激酶;当细胞受到糖皮质激素或者血清刺激后,SGK1的转录水平在30分钟内迅速升高,因此称之为血清和糖皮质激素调节蛋白激酶;SGK1与蛋白激酶B(PKB/Akt)等第二信使具有高度同源性,除了具有和绝大多数蛋白激酶相似的磷酸化/去磷酸化调节机制外,SGK1还受到快速转录阶段的调节。据文献报道,SGK1受到多种激素和生长因子的调节,如糖皮质激素、血清、盐皮质激素、多肽类激素CRH等均能快速诱导SGK1的表达。越来越多的研究表明,SGK1可能是多种细胞信号转导通路和细胞磷酸化级联反应的一个功能***汇点,存在参与离子通道调节、细胞存活、分化、增殖和凋亡的信号转导等多种生理功能。近来研究发现其与脑变性疾病如脑缺血、癫痫、阿尔茨海默病(AD)、帕金森氏病(PD)和脑肿瘤等密切相关,在中枢神经***发育、神经元变性、凋亡和脑肿瘤的发生发展过程中起着重要作用。SGK1 的表达及活性异常增加参与了多种疾病的发生及发展过程,SGK1的抑制剂被认为可能是治疗这些疾病的潜在的有用的药物。
c-Jun氨基末端激酶(c-Jun N-terminal kinase, JNK)家族是1990年被发现的促***原活化蛋白激酶(mitogen-activated protein kinase, MAPK)超家族成员之一,属于进化上保守的丝氨酸/苏氨酸蛋白激酶。J N K信号通路可被细胞因子、生长因子和应激等多种因素激活,在细胞增殖与分化、细胞凋亡和应激反应等多种细胞调控方面起着至关重要的作用。J N K信号通路功能失调可造成缺血再灌注损伤、慢性炎症、神经退行性变、糖尿病和肿瘤等多种疾病。近年来的研究发现过度激活的JNK信号通路与阿尔茨海默病、帕金森氏病密切相关,而敲除或JNK抑制剂则能改善AD和PD疾病模型的症状。有研究发现胶质瘤患者JNK高表达,且JNK的表达量与胶质瘤的恶性程度和胶质瘤患者的愈后密切相关。另外,JNK的抑制剂被发现能降低神经胶质瘤干细胞的自我更新能力,促进胶质瘤干细胞朝不具有致瘤能力的胶质样或神经元样的细胞分化。因此,JNK抑制剂被认为是神经退行性疾病和脑肿瘤等疾病的潜在药物。
硫辛酸(lipoic acid, LA)是已知天然抗氧剂中效果最强的一种,被誉为“万能抗氧剂”。它是丙酮酸脱氢酶的辅助因子,也是代谢性抗氧剂,在生物体内可以转化为还原型的二氢硫辛酸(DHLA),它可以通过清除自由基和活性氧;螯合金属离子、与其他体内的抗氧剂作用等途径达到抗氧化作用。硫辛酸具有分子量低和两亲性的特点,使得它容易透过血脑屏障,从而在中枢神经***发挥抗氧化作用,因此,它被认为是治疗神经退行性疾病的有效途径。但是硫辛酸在体内不够稳定,作用靶点较为单一,仅具有抗氧化作用,难以单独用于发病机制错综复杂的 CNS 疾病。临床上主要与其他药物联合使用,或作为多靶点药物研发的药效团。
由以上可以发现,SGK1和JNK均在中枢神经退行性疾病和脑肿瘤等疾病中高表达,抑制SGK1或JNK则能一定程度上改善中枢神经退行性疾病和脑肿瘤等疾病的病程,而抗氧化剂在治疗中枢神经退行性疾病中也起到了积极的作用。中枢神经退行性疾病和肿瘤等发病机制复杂且发病因素之间相互影响的复杂性疾病很难通过单一药物达到治疗或改善病情的目的。随着***生物和网络药理学的发展,人们越来越将这类疾病的治疗寄希望于能同时作用于与发病机制相关的多个靶点的多靶点药物上。基于此,本发明旨在开发具有同时抑制SGK1和JNK并具有抗氧化作用的小分子化合物,达到在中枢神经退行性疾病、脑肿瘤等疾病的治疗中起到相加或协同作用,同时减少联合用药带来的用药不方便、药物之间的相互作用等不良因素的目的。
发明内容
基于以上研究和多靶点药物研发理论,我们合成并筛选了一系列具有SGK1和JNK双靶点抑制作用的小分子化合物。
本发明涉及式(Ⅰ)的化合物或其互变异构体、药用盐、前药或溶剂化物。
其中结构式通式(Ⅰ)中
X为:
,
Y为:
,
Z为:
。
除非另外指明,本发明的化合物还意欲包括区别仅在于存在一个或多个同位素富集的原子的化合物。例如,用氘或氚替换氢,或者用13C或14C-富集的碳原子替换碳原子,或15N-富集的氮原子替换氮原子的化合物属于本发明的范围内。
属于“药用盐、衍生物、溶剂化物,前药”是指任何药用盐、酯、溶剂化物,或经施用于接受者后能够提供(直接或间接)本文所述化合物的其他化合物。然而,应当理解非药用盐也属于本发明的范围内,因为那些可能用于制备药用盐和盐,前药和衍生物的制备可以通过本领域已知的方法进行。例如,本发明提供的化合物的药用盐可以通过常规方法由母体化合物合成,该母体化合物含有碱或酸部分。通常,该盐例如通过将游离酸或碱形式的这些化合物与化学计算量的适当碱或酸在水中或在有机溶剂中或在两者的混合物中制备。通常,非水性介质如***、乙酸乙酯、乙醇、异丙醇或乙腈是优选的。酸加成盐的实例包括无机酸加成盐例如,盐酸盐、氢溴酸盐、氢碘酸盐、硫酸盐、硝酸盐,和有机酸加成盐例如,乙酸盐、马来酸盐、富马酸盐、柠檬酸盐、草酸盐、琥珀酸盐、酒石酸盐、苹果酸盐、扁桃酸盐和对甲苯磺酸盐。碱加成盐的实例包括无机盐如例如钠、钾、钙、铵、镁、铝和锂盐;和有机碱如例如乙二胺、乙醇胺、N, N-二烷基乙醇胺、三乙醇胺、葡糖胺和碱性氨基酸盐。
优选的衍生物或前药是相对于母体物质,当将这些化合物使用于患者时提高本发明化合物的生物利用度(例如通过使得口服给药的化合物更容易被吸收到血液中)或增强母体化合物向生物区室(例如脑或淋巴***)的传递的那些。
式(Ⅰ)化合物前药的任何化合物属于本发明的范围内,术语“前药”以其最广泛的意义使用并且包括在体内转化为本发明化合物的那些衍生物。这些衍生物对于本领域技术人员是显而易见的,并且根据分子中存在的官能团,包括不限于本发明化合物的下列衍生物:酯、氨基酸酯、磷酸、金属盐硫酸、氨基甲酸酯和酰胺。
本发明的化合物可以是作为有利化合物或作为溶剂化物的晶体形式,意欲将两种形式都包括在本发明的范围内。溶剂化的方法是本领域公知的。适当的溶剂化物是药用溶剂化物。在一个具体实施方案中,溶剂化物是水合物。
如果需要,可以通过常规方法如结晶法或色谱法纯化反应产物。当用于制备本发明化合物的上述方法产生立体异构体的混合物时,这些异构体可以通过常规技术如制备色谱法分离。如果存在手性中心,化合物可能以外消旋形式制备,或者可以通过对映特异性合成或通过拆分来制备单个的对映异构体。
一种优选的药用形式是结晶形式,包括药物组合物中的这种形式。如果是盐和溶剂化物,另外的离子或溶剂部分也应当是非毒性。本发明的化合物可以存在不同的多晶型物,意欲本发明包括所有这些形式。
由上述发明式(Ⅰ)表示的典型化合物、其盐、它们的溶剂化物或前药显示良好的血脑屏障透过率,较强的SGK1和JNK抑制作用。因此,本发明另一方面涉及治疗、改善或预防神经退行性疾病的方法,该方法包含向需要这种治疗的患者施用治疗有效量的式(Ⅰ)的化合物或其药物组合物。
本发明另外提供药物组合物,其包含本发明的化合物,或其药用盐、衍生物、前药或立体异构体,以及药用载体、辅剂或赋形剂,以用于向患者给药。
本发明的化合物和组合物可以与其它药物一起使用以提供联合治疗。其它药物可以形成相同组合物的一部分,或者可以作为同时或不同时给药的分开的组合物提供。
附图说明
图1. 化合物对谷氨酸诱导的HT22死亡的保护作用。*** P< 0.001,** P< 0.01,
** P< 0.05与谷氨酸组比较;### P< 0.001 与正常组比较。
图2. 化合物PT109对ROS的影响。
具体实施方式
提供下列实施例进一步举例说明本发明,它们不应当认为是对本发明范围的限定。除非特别说明,实施例中所涉及的试剂、方法均为本领域常用的试剂和方法。其中,DCM为二氯甲烷,TFA为三氟乙酸,EDCI为1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐,DMAP为4-二甲氨基吡啶。
实施例1
5-(1,2-二硫环戊烷-3-基)-N-(2-(异喹啉-5-磺酰胺)乙基)戊酰胺【5-(1,2-dithiolan-3-yl)-N-(2-(isoquinoline-5-sulfonamido)ethyl)pentanamide】(PT019)的制备:
合成路线:
按照上述PT019的合成路线,将异喹啉-5-磺酸置于圆底烧瓶中,加入6mL二氯亚砜和一滴DMF,回流三个小时。用旋转蒸发仪除去二氯亚砜,向剩余固体中加入DCM,过滤,固体用DCM洗涤三次后经真空干燥箱干燥得到白色固体中间体2(1g, 产率91.9%)。
在冰浴条件下,将中间体2(130.00mg,571.01μmol )缓慢地加入含有乙二胺(381.30μL,5.71mmol)的DCM (6mL)溶液中,撤去冰浴后室温反应3h。反应完成后用水洗去剩余的乙二胺,有机相用旋转蒸发仪除去溶剂,剩余物在***中重结晶得到棕黄色固体中间体3(91.8mg, 产率60%)。1H NMR (400 MHz, DMSO) δ 9.48 (s, 1H), 8.70 (d, J =6.1 Hz, 1H), 8.47 – 8.40 (m, 2H), 8.34 (dd, J = 7.4, 1.1 Hz, 1H), 7.87 – 7.80(m, 1H), 2.77 (t, J = 6.5 Hz, 2H), 2.46 (t, J = 6.5 Hz, 2H).
将中间体3(100mg,397.92μmol),硫辛酸(98.52mg,477.51μmol),DMAP(4.86mg,39.79μmol)溶于DCM(6mL)中,将Et3N(165.48μL,1.19mmol) 和 EDCI (114.42mg,596.88μmol)加入溶液中,反应在室温下搅拌过夜后加入DCM(30 mL)稀释,用水(10 mL)终止反应。分离后,水相用DCM(15 mL×3)萃取。合并的有机相用饱和的食盐水(10mL×1)洗涤。在Na2SO4干燥后旋蒸除去溶剂,残留物经硅胶柱色谱纯化得到黄色粘稠油状物PT019(168mg, 产率96%)。1HNMR (400 MHz,CDCl3) δ 9.36 (s, 1H), 8.70 (d, J = 6.1 Hz, 1H), 8.48 – 8.35 (m,2H), 8.22 (d, J = 8.2 Hz, 1H), 7.77 – 7.65 (m, 1H), 5.94 (dd, J = 10.0, 4.8Hz, 2H), 3.56 (dt, J = 14.8, 6.3 Hz, 1H), 3.34 (dd, J = 11.1, 5.8 Hz, 2H),3.14 (dddd, J = 22.8, 16.0, 8.9, 5.5 Hz, 4H), 2.46 (dt, J = 12.3, 6.5 Hz,1H), 2.16 – 2.03 (m, 2H), 1.91 (td, J = 13.7, 6.9 Hz, 1H), 1.61 – 1.53 (m,2H), 1.48 – 1.32 (m, 2H).13C NMR (101 MHz, CDCl3) δ 174.29, 153.28, 145.02,134.25, 133.69, 133.23, 131.17, 129.08, 126.08, 117.36, 56.46, 43.28, 40.28,39.38, 38.49, 36.14, 34.50, 28.78, 25.21.纯度:97% (高效液相色谱法)。
实施例2
5-(1,2-二硫环戊烷-3-基)-N-(3-(异喹啉-5-磺酰胺)丙基)戊酰胺【5-(1,2-dithiolan-3-yl)-N-(3-(isoquinoline-5-sulfonamido)propyl)pentanamide】(PT046)的制备:
合成路线:
按照上述PT046的合成路线,在冰浴条件下,将实施例1中获得到中间体2(600.00mg,2.27mmol)缓慢地加入含有1,3-丙二胺(1.89mL, 22.72mmol)的DCM (6 mL)溶液中,撤去冰浴后室温反应3h. 反应完成后用水洗去剩余的乙二胺,有机相用旋转蒸发仪除去溶剂,剩余物在***中重结晶得到棕黄色固体中间体4(300mg, 产率43.8%)。
将中间体4(77.16mg,290.80μmol ),硫辛酸(50.00mg, 242.34μmol),DMAP(2.96mg, 24.23μmol)溶于DCM(6mL)中,将Et3N(6mL) 和 EDCI (69.68mg, 363.50μmol)加入溶液中,反应在室温下搅拌过夜后加入DCM(30 mL)稀释,用水(10 mL)终止反应。分离后,水相用DCM(15 mL×3)萃取。合并的有机相用饱和的食盐水(10mL×1)洗涤。在Na2SO4干燥后旋蒸除去溶剂,残留物经硅胶柱色谱纯化得到黄色粘稠油状物PT046(19.2mg, 产率17.5%)。1H NMR (400 MHz, CDCl3) δ 9.34 (s, 1H), 8.70 (d, J = 6.1 Hz, 1H), 8.47 (d,J = 6.1 Hz, 1H), 8.41 (dd, J = 7.3, 1.1 Hz, 1H), 8.19 (d, J = 8.2 Hz, 1H),7.73 – 7.63 (m, 1H), 6.49 (t, J = 6.5 Hz, 1H), 5.82 (t, J = 5.9 Hz, 1H), 3.52– 3.43 (m, 1H), 3.28 (dd, J = 12.2, 6.3 Hz, 2H), 3.20 – 3.04 (m, 2H), 2.92(dd, J = 12.2, 6.4 Hz, 2H), 2.48-2.38 (m, 1H), 2.11 (t, J = 7.3 Hz, 2H), 1.94– 1.77 (m, 4H), 1.70 – 1.62 (m, 1H), 1.55 – 1.46 (m, 2H), 1.40 – 1.28 (m,2H).13C NMR (101 MHz, CDCl3) δ 174.10, 153.16, 145.16, 135.06, 133.35, 132.85,131.26, 129.05, 125.94, 117.55, 56.42, 40.27, 39.73, 38.48, 36.26, 35.80,34.48, 30.10, 28.76, 25.25. 纯度:96% (高效液相色谱法)。
实施例3
5-(1,2-二硫环戊烷-3-基)-N-(4-(异喹啉-5-氨基)环己基)戊酰胺【5-(1,2-dithiolan-3-yl)-N-(4-(isoquinolin-5-ylamino)cyclohexyl)pentanamide】(PT109)的制备:
合成路线:
按照上述PT109的合成路线,将化合物5 (442.31mg, 2.07mmol),5-氨基异喹啉(230.00mg, 1.60mmol)和无水Na2SO4 (1.13g, 7.98mmol)溶于冰醋酸(10mL)中,在冰浴条件下加入氰基硼氢化钠(200.50mg, 3.19mmol),撤掉冰浴,反应在室温搅拌下过夜。反应完成后用旋转蒸发仪除去冰醋酸,剩余物中加入饱和NaHCO3溶液,水相用DCM萃取。合并的有机相用饱和的食盐水(10mL×1)洗涤,在无水Na2SO4干燥后旋蒸除去溶剂,残留物经硅胶柱色谱纯化得到黄色固体化合物6(372mg, 产率68.3%)。1H NMR (400 MHz, CDCl3) δ 9.15(s, 1H), 8.46 (s, 1H), 7.53 (s, 1H), 7.49 – 7.39 (m, 1H), 7.30 (s, 1H), 6.77(s, 1H), 4.71 – 4.12 (m, 2H), 3.55 (m, 3H), 2.27 (d, J = 12.0 Hz, 1H), 2.14(d, J = 12.6 Hz, 1H), 2.06 – 1.88 (m, 2H), 1.82 (m, 2H), 1.46 (s, 9H), 1.34(m, 3H).
将化合物6 (45.51mg,133.28μmol)溶解在DCM (1 mL)中,加入TFA (1 mL),室温下搅拌3小时。反应完成后用旋转蒸发仪除去TFA,剩余物中加入硫辛酸(25.00mg,121.17μmol),HOBt (18.01mg, 133.28μmol)和EDCI(34.84mg, 181.75μmol),加入含有三乙胺(50.39μL,363.50μmol)的无水DCM,室温下搅拌过夜,反应完成后加水(10mL)萃灭,水相用DCM萃取,合并的有机相用饱和的食盐水(10mL×1)洗涤,在无水Na2SO4干燥后旋蒸除去溶剂,残留物经硅胶柱色谱纯化得到黄色油状物PT109(39.3mg,产率75.5%)。m.p.131.4℃. 1H NMR (400MHz, CDCl3) δ 9.14 (s, 1H), 8.44 (d, J = 5.9 Hz, 1H), 7.54 (d, J = 5.9 Hz,1H), 7.46 (t, J = 7.9 Hz, 1H), 7.30 (d, J = 8.1 Hz, 1H), 6.77 (d, J = 7.7 Hz,1H), 6.00 (d, J = 7.4 Hz, 1H), 4.01 (d, J = 7.4 Hz, 1H), 3.70 (s, 1H), 3.62 –3.48 (m, 1H), 3.24 – 3.02 (m, 2H), 2.43 (tt, J = 20.8, 10.4 Hz, 1H), 2.20 (t,J = 7.3 Hz, 2H), 2.00 – 1.78 (m, 7H), 1.70 (m, 7H), 1.56 – 1.37 (m, 3H). 13CNMR (100 MHz, CDCl3) δ 173.25, 171.31, 153.00, 143.11, 131.58, 130.07,129.03, 127.30, 125.40, 114.24, 56.46, 45.00, 43.66, 41.11, 40.28, 38.53,34.73, 33.13, 29.19, 28.93, 25.06.纯度: 100% (高效液相色谱法)。
实施例4
5-(1,2-二硫环戊烷-3-基)-1-(3-(异喹啉-5-氨基)哌啶-1-基)戊烷-1-酮【5-(1,2-dithiolan-3-yl)-1-(3-(isoquinolin-5-ylamino)piperidin-1-yl)pentan-1-one】(PT128)的制备:
合成路线:
按照上述PT128的合成路线,将化合物7(497.52mg, 2.50mmol),5-氨基异喹啉(300.00mg, 2.08mmol)溶解在钛酸异丙酯(5mL)中,室温下搅拌30分钟后加入无水乙醇(5mL)稀释,冰浴条件下加入氰基硼氢化钠(261.53mg,4.16mmol),反应在室温下搅拌3个小时。用硅藻土过滤去除固体物,加入饱和NaHCO3溶液淬灭反应,水相用乙酸乙酯萃取,合并的有机相用饱和的食盐水(10mL×1)洗涤,在无水Na2SO4干燥后旋蒸除去溶剂,残留物经硅胶柱色谱纯化得到黄色固体化合物8(566.00mg, 产率83%)。
将化合物8(200.00mg, 610.83μmol)溶解在DCM (1 mL)中,加入TFA (1 mL),室温下搅拌3小时。反应完成后用旋转蒸发仪除去TFA,加入饱和NaHCO3溶液(10mL),水相用乙酸乙酯萃取,合并的有机相用饱和的食盐水(10mL×1)洗涤,在无水Na2SO4干燥后旋蒸除去溶剂,残留物经硅胶柱色谱纯化得到黄色固体(130.00mg, 产率93.6%)。
将硫辛酸(50.00mg, 242.34μmol)溶解到DMF (3 mL)中,加入EDCI (139.37mg,727.01μmol),HOBt (39.29mg,290.80μmol)和三乙胺(100.78μL,727.01μmol)在室温下搅拌10分钟后一次性加入上述反应得到的黄色固体(71.61mg,315.04μmol),室温氩气保护搅拌6小时,加入饱和NaHCO3溶液水相用乙酸乙酯萃取,合并的有机相用饱和的食盐水(10mL×1)洗涤,在无水Na2SO4干燥后旋蒸除去溶剂,残留物经硅胶柱色谱纯化得到棕黄色油状物(53mg,产率52.6%)。1H NMR (400 MHz, DMSO) δ 9.12 (s, 1H), 8.40 (s, 1H), 8.14 –8.02 (m, 1H), 7.46 (d, J = 4.7 Hz, 1H), 7.28 (t, J = 7.0 Hz, 1H), 6.93 – 6.80(m, 1H), 6.12 – 5.98 (m, 1H), 4.63 (d, J = 12.4 Hz, 1H), 4.03 (d, J = 11.9Hz, 1H), 3.85 (d, J = 12.0 Hz, 1H), 3.62 (s, 2H), 3.51 (s, 1H), 3.24 – 2.99(m, 4H), 2.91 (s, 1H), 2.43 – 2.30 (m, 2H), 2.15 (dd, J = 38.2, 16.6 Hz, 3H),1.93 – 1.65 (m, 5H), 1.63 – 1.33 (m, 7H), 1.22 (s, 1H).纯度:99% (高效液相色谱法)。
实施例5
1-(5-(1,2-二硫环戊烷-3-基)戊酰基-N-(异喹啉-5-基)哌啶-4-甲酰胺【1-(5-(1,2-dithiolan-3-yl)pentanoyl)-N-(isoquinolin-5-yl)piperidine-4-carboxamide】(PT106)的制备:
合成路线:
按照上述PT106的合成路线,将化合物9(1 g, 7.74mmol)溶解在NaOH溶液(2 M, 10mL)中,在冰浴条件下缓慢加入溶解了BOC酸酐(2.53g, 11.61mmol)的THF (10 mL)溶液,反应在室温下搅拌1小时,用旋转蒸发仪除去THF,水相用稀盐酸调节pH值至5-6,然后用乙酸乙酯萃取,合并的有机相用无水Na2SO4干燥并过滤,滤液用旋转蒸发仪浓缩,真空干燥后得到白色固体化合物10(1.78g, 7.76mmol, 产率100%)。
将化合物10 (279.89mg, 1.22mmol),5-氨基异喹啉(160.00mg, 1.11mmol),DMAP(13.56mg, 110.98μmol)溶解在无水DCM(8ml)中,常温下加入三乙胺(461.50μL,3.33mmol)和EDCI(319.12mg,1.66mmol),室温下搅拌过夜;反应完成后加水(10mL)淬灭,水相用DCM萃取,合并的有机相用饱和的食盐水(10mL×1)洗涤,在无水Na2SO4干燥后旋蒸除去溶剂,残留物经硅胶柱色谱纯化得到白色固体中间体11(174.30mg, 490.39μmol, 产率44.2%)。 1HNMR (400 MHz, CDCl3) δ 9.27 (s, 1H), 8.57 (d, J = 6.0 Hz, 1H), 8.16 (d, J =7.2 Hz, 1H), 7.84 (d, J = 8.2 Hz, 1H), 7.64-7.57 (m, 3H), 4.37 – 4.10 (m,2H), 2.86 (s, 2H), 2.59 (s, 1H), 2.05-2.01 (m, 2H), 1.89-1.79 (m, 2H), 1.48(s, 9H).
将中间体11(85.00mg, 239.15μmol) 溶解在DCM (1 mL)中,加入TFA (1 mL),室温下搅拌3小时。反应完成后用旋转蒸发仪除去TFA,剩余物中加入硫辛酸(59.21mg, 286.98μmol),DMAP(2.92mg, 23.91μmol)和EDCI(91.69mg,478.29μmol),加入含有三乙胺(99.45μL,717.44μmol)的无水DCM,室温下搅拌过夜,反应完成后加水(10mL)萃灭,水相用DCM萃取,合并的有机相用饱和的食盐水(10mL×1)洗涤,在无水Na2SO4干燥后旋蒸除去溶剂,残留物经硅胶柱色谱纯化得到黄色油状物PT106(77mg, 173.57μmol, 产率72.6%)。1H NMR (400MHz, CDCl3) δ 9.22 (s, 1H), 8.51 (d, J = 5.9 Hz, 1H), 8.12 (s, 1H), 8.06 (d,J = 7.4 Hz, 1H), 7.81 (d, J = 8.1 Hz, 1H), 7.60-7.56 (m, 2H), 4.65 (d, J =12.8 Hz, 1H), 3.96 (d, J = 13.3 Hz, 1H), 3.59 - 3.52 (m, 1H), 3.23 – 3.05 (m,3H), 2.76-2.67 (m, 11.2 Hz, 2H), 2.48-2.40 (m, 1H), 2.38 – 2.27 (m, 2H), 2.05(d, J = 12.5 Hz, 2H), 1.96 – 1.84 (m, 5H), 1.84 – 1.74 (m, 2H), 1.70-1.59 (m,4H), 1.52 – 1.40 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 173.34, 171.40, 153.09,143.20, 131.67, 130.16, 129.12, 127.39, 125.49, 114.33, 56.55, 45.09, 43.75,41.20, 40.37, 38.62, 34.82, 33.22, 29.19, 25.15.纯度:96% (高效液相色谱法)。
实施例6
4-(5-(1,2-二硫环戊烷-3-基)戊酰胺)-N-(异喹啉-5-基)苯甲酰胺【4-(5-(1,2-dithiolan-3-yl)pentanamido)-N-(isoquinolin-5-yl)benzamide】(PT133)的制备:
合成路线:
按照上述PT133的合成路线,将化合物12(200.00mg, 1.39mmol),5-氨基异喹啉(427.86mg,1.80mmol),DMAP (16.95mg, 138.72umol),三乙胺(576.87μL, 4.16mmol)溶解在无水DCM中,室温下搅拌30分钟后一次性加入EDCI (797.80mg, 4.16mmol),回流反应过夜;反应完成后加水(10mL)淬灭,水相用DCM萃取,合并的有机相用饱和的食盐水(10mL×1)洗涤,在无水Na2SO4干燥后旋蒸除去溶剂,残留物经硅胶柱色谱纯化得到白色固体中间体13(426, 1.17mmol, 产率84.5%)。1H NMR (400 MHz, DMSO) δ 10.36 (s, 1H), 9.71 (s,1H), 9.35 (s, 1H), 8.52 (d, J = 5.9 Hz, 1H), 8.03 (t, J = 8.3 Hz, 3H), 7.88(d, J = 7.3 Hz, 1H), 7.82 (d, J = 5.6 Hz, 1H), 7.72 (t, J = 7.7 Hz, 1H), 7.63(d, J = 8.1 Hz, 2H), 1.51 (s, 9H).
将中间体13(80.00mg,220.14μmol)溶解在DCM(1 mL)中,加入TFA (1 mL),室温下搅拌3小时。反应完成后用旋转蒸发仪除去TFA,剩余物中加入硫辛酸(54.50mg,264.16μmol),DMAP(2.69mg,22.01μmol)和EDCI(126.60mg, 660.41μmol),加入含有三乙胺(91.54μL,660.41μmol)的无水DCM(6mL),室温下搅拌过夜,反应完成后加水(10mL)萃灭,水相用DCM萃取,合并的有机相用饱和的食盐水(10mL×1)洗涤,在无水Na2SO4干燥后旋蒸除去溶剂,残留物经硅胶柱色谱纯化得到白色固体PT133(54.40mg, 120.46μmol, 产率54.7%)。m.p.172.6℃.1H NMR (400 MHz, DMSO) δ 10.41 (s, 1H), 10.20 (s, 1H), 9.38 (s, 1H), 8.53(d, J = 6.0 Hz, 1H), 8.08 – 8.03 (m, 3H), 7.91 (d, J = 7.3 Hz, 1H), 7.85 (d,J = 6.0 Hz, 1H), 7.78 (s, 1H), 7.76 (d, J = 2.3 Hz, 1H), 7.73 (d, J = 7.8 Hz,1H), 3.69-3.60 (m, 1H), 3.21-3.13 (m, 3H), 2.46 – 2.35 (m, 3H), 1.83-1.93 (m,1H), 1.78 – 1.55 (m, 4H), 1.47-1.42 (m, 2H). 13C NMR (100 MHz, DMSO) δ 172.11,166.12, 152.97, 143.15, 142.98, 133.77, 131.84, 129.33, 128.73, 127.80,127.66, 126.00, 118.72, 116.89, 113.08, 56.59, 38.60, 36.80, 34.64, 28.82,25.24.纯度: 97% (高效液相色谱法)。
实施例7
4-(5-(1,2-二硫环戊烷-3-基)戊酰胺)N-(吡啶-4-基)苯甲酰胺【4-(5-(1, 2-dithiolan-3-yl)pentanamido)-N-(pyridin-4-yl)benzamide】(PT119)的制备:
合成路线:
按照上述PT119的合成路线,将化合物14 (1.00g,5.15mmol)溶解在DCM (2 mL)中,加入TFA (2 mL),室温下搅拌3小时。反应完成后用旋转蒸发仪除去TFA,得到4-氨基吡啶三氟乙酸盐粗品。
将4-氨基吡啶三氟乙酸盐(300.00mg, 1.45mmol),N-BOC-4-氨基苯甲酸(377.99mg,1.59mmol),DMAP(17.69mg,144.84μmol)溶解在无水DCM(6mL)中,室温下加入三乙胺(602.30μL,4.35mmol)和EDCI (416.48mg,2.17mmol),室温下搅拌过夜,反应完成后加水(10mL)萃灭,水相用DCM萃取,合并的有机相用饱和的食盐水(10mL×1)洗涤,在无水Na2SO4干燥后旋蒸除去溶剂,残留物经硅胶柱色谱纯化得到白色固体中间体15(140mg,446.78μmol,产率30.85%)。1H NMR (400 MHz, DMSO) δ 10.41 (s, 1H), 9.72 (s, 1H),8.45 (d, J = 4.6 Hz, 2H), 7.90 (d, J = 8.3 Hz, 2H), 7.77 (d, J = 4.9 Hz, 2H),7.60 (d, J = 8.3 Hz, 2H), 1.49 (s, 9H).
将中间体15(50.00mg, 159.57μmol)溶解在DCM (1 mL)中,加入TFA (1 mL),室温下搅拌3小时。反应完成后用旋转蒸发仪除去TFA,剩余物中加入硫辛酸(32.92mg,159.57μmol),HOBt (25.87mg,191.48μmol)和EDCI(45.88mg,239.35μmol),加入含有三乙胺(66.36μL,478.70μmol)的无水DMF(4mL)溶液,室温下搅拌过夜,反应完成后加水(10mL)萃灭,水相用DCM萃取,合并的有机相用饱和的食盐水(10mL×1)洗涤,在无水Na2SO4干燥后旋蒸除去溶剂,残留物经硅胶柱色谱纯化得到白色固体PT119(48mg, 119.54μmol, 产率74.91%)。m.p.159.9℃.1H NMR (400 MHz, DMSO) δ 10.44 (s, 1H), 10.21 (s, 1H), 8.45 (s, 2H),7.94 (d, J = 7.4 Hz, 2H), 7.75 (d, J = 9.1 Hz, 4H), 3.63 (s, 1H), 3.15 (d, J= 20.1 Hz, 2H), 2.36 (s, 3H), 1.90-1.86 (m, 1H), 1.61 (s, 4H), 1.42 (s, 2H).13C NMR (100 MHz, DMSO) δ 171.64, 165.72, 150.19, 146.05, 142.75, 128.86,128.11, 118.20, 113.94, 56.07, 38.08, 36.27, 34.11, 28.27, 24.69.纯度: 97%(高效液相色谱法)。
实施例8
1-(5-(1,2-二硫环戊烷-3-基)戊酰胺)-N-(吡啶-4-基)哌啶-4-甲酰胺【1-(5-(1,2-dithiolan-3-yl)pentanoyl)-N-(pyridin-4-yl)piperidine-4-carboxamide】(PT134)的制备:
合成路线:
按照上述PT134的合成路线,将实施例7中获得的4-氨基吡啶三氟乙酸盐(200.00mg,965.58μmol),化合物10(265.66mg,1.16mmol),DMAP(11.80mg,96.56μmol)溶解在无水DCM(6mL)中,加入三乙胺(401.53μL,2.90mmol)和EDCI (555.31mg,2.90mmol),室温下搅拌过夜,反应完成后加水(10mL)萃灭,水相用DCM萃取,合并的有机相用饱和的食盐水(10mL×1)洗涤,在无水Na2SO4干燥后旋蒸除去溶剂,残留物经硅胶柱色谱纯化得到白色固体中间体16(281mg, 920.19μmol, 产率95.3%)。1H NMR (400 MHz, DMSO) δ 10.29 (s, 1H), 8.40(d, J = 4.8 Hz, 2H), 7.56 (d, J = 4.8 Hz, 2H), 3.99 (d, J = 14.2 Hz, 3H),2.86-2.67 (m, 2H), 1.79 (d, J = 12.9 Hz, 2H), 1.51-1.45(m, 2H), 1.40 (s, 9H).将化合物16(140.00mg, 458.46μmol) 溶解在DCM (1 mL)中,加入TFA (1 mL),室温下搅拌3小时。反应完成后用旋转蒸发仪除去TFA,剩余物中加入硫辛酸(113.51mg,550.15μmol),DMAP (5.60mg,45.85μmol)和EDCI (263.66mg,1.38mmol)和DMF(1mL),最后加入溶解了三乙胺(190.65μL,1.38mmol)的无水DCM(6mL),室温下搅拌过夜,反应完成后加水(10 mL)萃灭,水相用DCM萃取,合并的有机相用饱和的食盐水(10mL×1)洗涤,在无水Na2SO4干燥后旋蒸除去溶剂,残留物经硅胶柱色谱纯化得到棕黄色油状物PT134(154.3mg, 392.06μmol,产率85.52%)。1H NMR (400 MHz, CDCl3) δ 8.47 (d, J = 5.3 Hz, 2H), 8.34 (s, 1H),7.51 (d, J = 5.4 Hz, 2H), 4.59 (d, J = 13.4 Hz, 1H), 3.94 (d, J = 13.5 Hz,1H), 3.66 – 3.48 (m, 1H), 3.25 – 3.01 (m, 3H), 2.68 (t, J = 12.2 Hz, 1H),2.59 – 2.41 (m, 2H), 2.35 (t, J = 7.4 Hz, 2H), 1.94-1.91 (m, 2H), 1.81-1.79(m, 1H), 1.72-1.63 (m, 6H), 1.52-1.45 (m, 3H).13C NMR (100 MHz, CDCl3) δ173.78, 171.51, 150.35, 145.93, 113.98, 56.53, 45.02, 43.83, 41.17, 40.37,38.61, 34.79, 33.21, 29.14, 25.19.纯度: 98% (高效液相色谱法)。
实施例9:生物学评估
化合物对谷氨酸诱导的HT22死亡的保护作用
取对数生长期HT-22细胞,以0.25%胰酶消化后,完全培养基重悬,显微镜下细胞计数板计数并调整细胞浓度为10×104个/mL,接种96孔细胞培养板,100 μL/孔,培养过夜,使细胞贴壁。将96孔板中培养基吸走,加入不同浓度的化合物到96孔板中,100 μL/孔。预孵育30min后,加入2 μL 100mM L-glutamate。模型组不加待测化合物,直接加入2μL 100mM L-glutamate。孵育24h后,每孔加入10 μL 5mg/mL MTT,孵育1h,弃去上清,加 DMSO 100 μL/孔,振荡使生成物formazan充分溶解,在酶标仪上测定各孔吸光度值,测定波长570 nm。采用公式化合物促进细胞的存活率(%)=100%*(A待测化合物-A模型组) / (A模型组-A空白)计算细胞存活率。结果见附图1。从结果可以看出,除化合物PT119外,其他化合物均能在一定的浓度下逆转谷氨酸诱导的HT-22细胞的死亡。
实施例10:生物学评估
PT109对ROS的影响
采用DHE染色检测氧自由基的生成情况。HT-22细胞用DMEM +10%胎牛血清,并置于37℃,含5% CO2孵箱中。将细胞以合适的密度种在多聚赖氨酸包被的24孔板;待细胞贴壁后,分别用培养基配制好的PT109加入对应的孔中,处理30 min后,加入2 mM谷氨酸处理10 h。收集细胞,并用DHE染料孵育细胞30 min左右,洗净DHE染料,用高内涵***检测DHE的荧光强度。实验结果显示PT109在10μM条件下能明显减少由谷氨酸诱导的ROS升高。
实施例11:生物学评估
PT109对SGK1和JNK的抑制作用
通过life Technologies公司的激酶筛选商业化服务检测PT109对SGK和JNK的抑制作用。结果如表1所示:PT109对SGK1、SGK2和SGK3的IC50为分别为1.34μM、5.6μM和26.4μM,对SGK1有较好的选择性;对JNK1、JNK2和JNK3的IC50分别为0.285μM、0.143μM和0.831μM。
表1 PT109对JNK和SGK1的抑制作用
实施例12:生物学评估
PT109的激酶选择性
通过life Technologies公司的激酶筛选服务检测PT109对其他激酶(包括JNK和SGK1)的抑制作用(化合物9的浓度为10μM,重复两次取平均值),考察化合物对JNK和SGK1的选择性。结果如表2所示:PT109在10μM的条件下对SGK1和JNK具有较好的选择性。
表2 PT109对其他激酶的筛选结果
Kinase Tested | % Inhibition | Kinase Tested | % Inhibition |
ADRBK1 (GRK2) | 6 | PRKCA (PKC alpha) | 25 |
AKT1 (PKB alpha) | 22 | PRKCB1 (PKC beta I) | -10 |
AKT2 (PKB beta) | 30 | PRKCG (PKC gamma) | 63 |
AURKC (Aurora C) | 5 | PRKCH (PKC eta) | -17 |
CDK1/cyclin B | 14 | PRKCI (PKC iota) | -14 |
CDK5/p25 | 18 | PTK2B (FAK2) | 8 |
CDK5/p35 | 26 | PTK6 (Brk) | 7 |
CSNK1A1 (CK1 alpha 1) | 3 | RPS6KA3 (RSK2) | 54 |
CSNK1D (CK1 delta) | 6 | RPS6KA4 (MSK2) | 28 |
CSNK1E (CK1 epsilon) | 10 | SGK (SGK1) | 91 |
CSNK1G1 (CK1 gamma 1) | 9 | SRMS (Srm) | 20 |
CSNK1G2 (CK1 gamma 2) | 15 | STK22D (TSSK1) | -2 |
CSNK1G3 (CK1 gamma 3) | 24 | TAOK2 (TAO1) | -6 |
CSNK2A1 (CK2 alpha 1) | 14 | TBK1 | 10 |
CSNK2A2 (CK2 alpha 2) | 11 | TYRO3 (RSE) | 12 |
DYRK1A | 16 | CHUK (IKK alpha) | 16 |
EGFR (ErbB1) | -6 | PI4KB (PI4K beta) | 39 |
FGFR1 | -3 | PIK3C2A (PI3K-C2 alpha) | 3 |
FGFR4 | -2 | PIK3C3 (hVPS34) | 11 |
FLT1 (VEGFR1) | 3 | PIK3CA/PIK3R1 (p110 alpha/p85 alpha) | 56 |
GRK5 | 2 | PIK3CD/PIK3R1 (p110 delta/p85 alpha) | 48 |
GSK3A (GSK3 alpha) | 41 | PIK3CG (p110 gamma) | 9 |
GSK3B (GSK3 beta) | 61 | MAP2K1 (MEK1) S218D S222D | 13 |
HCK | 9 | MAP3K2 (MEKK2) | 10 |
HIPK1 (Myak) | 0 | MAP3K3 (MEKK3) | 3 |
LTK (TYK1) | 40 | MAP3K5 (ASK1) | 9 |
MAP3K9 (MLK1) | 2 | MAP3K7/MAP3K7IP1 (TAK1-TAB1) | 39 |
MAP4K4 (HGK) | 34 | MAPK10 (JNK3) | 90 |
MAPK1 (ERK2) | 4 | MAPK8 (JNK1) | 104 |
MST1R (RON) | 35 | MAPK9 (JNK2) | 91 |
NEK4 | 3 | MKNK2 (MNK2) | 26 |
NEK6 | 3 | MYO3B (MYO3 beta) | 43 |
NEK7 | 2 | PLK4 | 35 |
NTRK1 (TRKA) | 35 | SLK | 5 |
NTRK3 (TRKC) | 28 | TEC | 26 |
PAK6 | -16 | TLK1 | 20 |
PDGFRB (PDGFR beta) | 7 | ULK1 | 26 |
PDK1 Direct | 51 | ULK2 | 4 |
PDK1 | 5 | WNK2 | 13 |
PHKG1 | 10 | WNK3 | 7 |
PKN1 (PRK1) | 16 |
实施例13:生物学评估
体外血脑屏障透过率
1) 取4 µL 2%(PBL)溶液加于MAIPn 4550的96孔板的疏水膜上,滴加过程中注意移液枪头勿接触膜表面以防破坏膜结构;
2)迅速(10 min内)定量吸取200 µL待测样品液(0.1 mg/ml)加入到96孔板中的膜上方作为给药池,膜另一侧加入200 µL PBS (pH=7.4)为接受池,注意保持接受液与膜的充分接触;
3)室温静止120 min后,小心移除给药池,用UV光谱仪测试接受池内化合物吸光度值(250-500 nm);
4)吸取100 µL待测样品液与100 µL PBS充分混匀,作为理论平衡溶液,测试其吸光度值(250-500 nm),需要用acceptor板测试;
5)根据公式计算logPe值:
式中Vd是接受池的体积,Va是接受池的体积,A是膜面积,t是渗透时间,[drug]acceptor是接受池的吸光度,[drug]equilibrium是理论平衡吸光度。
注:P e×10-6 cm s-1值大于5.3,则化合物能够透过血脑屏障,小于2.4被定义为不能透过血脑屏障。由结果表3可知,PT109具有较好的血脑屏障透过率。
表3 PT109的血脑屏障透过率
Compound | P e(×10-6 cm s-1) | Prediction | M.W | cLogP |
PT109 | 11.93±0.08 | CNS+ | 429.19 | 4.26 |
Claims (6)
1.一种具有下述结构式的化合物或其药用盐:
式()
其中,
X选自:
;
Y选自:
;
Z选自:
。
2.一种药物组合物,包括如权利要求1所述的任一化合物或其药用盐,以及药学上可接受的载体或赋形剂。
3.权利要求1的任一化合物或其药用盐在制备治疗中枢神经***退行性疾病或脑肿瘤的药物中的应用。
4.根据权利要求3所述的应用,所述中枢神经***退行性疾病包括阿尔茨海默病或帕金森氏病。
5.根据权利要求3所述的应用,所述脑肿瘤包括胶质瘤。
6.一种具有抗氧化作用的SGK1和JNK双靶点抑制剂,其包含权利要求1所述的任一化合物或其药用盐。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610667749.0A CN106279136B (zh) | 2016-08-15 | 2016-08-15 | 治疗中枢神经***退行性疾病或脑肿瘤的化合物及其应用 |
PCT/CN2016/109199 WO2018032666A1 (zh) | 2016-08-15 | 2016-12-09 | 治疗中枢神经***退行性疾病或脑肿瘤的化合物及其应用 |
US16/325,669 US10723724B2 (en) | 2016-08-15 | 2016-12-09 | Compounds for treating degenerative diseases of central nervous system or brain tumor, and uses thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610667749.0A CN106279136B (zh) | 2016-08-15 | 2016-08-15 | 治疗中枢神经***退行性疾病或脑肿瘤的化合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106279136A true CN106279136A (zh) | 2017-01-04 |
CN106279136B CN106279136B (zh) | 2019-06-21 |
Family
ID=57670887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610667749.0A Active CN106279136B (zh) | 2016-08-15 | 2016-08-15 | 治疗中枢神经***退行性疾病或脑肿瘤的化合物及其应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US10723724B2 (zh) |
CN (1) | CN106279136B (zh) |
WO (1) | WO2018032666A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2022002720A (es) * | 2019-09-05 | 2022-08-10 | Lunan Pharmaceutical Group Corp | Inhibidor de magl, procedimiento de preparacion y uso del mismo. |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3238224A (en) * | 1960-06-17 | 1966-03-01 | Fujisawa Pharmaceutical Co | Production of 6, 8-dithiooctanoyl amides |
CN102970966A (zh) * | 2009-11-09 | 2013-03-13 | 莱雅公司 | 具有杂环二硫化物单元的新型染料、包含它们的着色组合物和以这些染料为基础将人角蛋白纤维染色的方法 |
CN103582680A (zh) * | 2011-05-03 | 2014-02-12 | 巴斯夫欧洲公司 | 二硫化物染料 |
CN103649077A (zh) * | 2011-06-29 | 2014-03-19 | 阿达梅德公司 | 用于治疗中枢神经***疾病的脂环族胺类的磺酰胺衍生物 |
CN104220421A (zh) * | 2012-03-20 | 2014-12-17 | 阿达梅德公司 | 用于治疗中枢神经***疾病的苄胺的磺酰胺衍生物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3372365B2 (ja) * | 1994-08-19 | 2003-02-04 | 富士写真フイルム株式会社 | ハロゲン化銀写真感光材料およびそれを用いた画像形成方法 |
AR042572A1 (es) * | 1999-04-02 | 2005-06-29 | Sod Conseils Rech Applic | Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos |
CN105949180B (zh) | 2016-05-10 | 2018-07-10 | 中山大学 | 治疗中枢神经***退行性疾病的化合物及其应用 |
-
2016
- 2016-08-15 CN CN201610667749.0A patent/CN106279136B/zh active Active
- 2016-12-09 WO PCT/CN2016/109199 patent/WO2018032666A1/zh active Application Filing
- 2016-12-09 US US16/325,669 patent/US10723724B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3238224A (en) * | 1960-06-17 | 1966-03-01 | Fujisawa Pharmaceutical Co | Production of 6, 8-dithiooctanoyl amides |
CN102970966A (zh) * | 2009-11-09 | 2013-03-13 | 莱雅公司 | 具有杂环二硫化物单元的新型染料、包含它们的着色组合物和以这些染料为基础将人角蛋白纤维染色的方法 |
CN103582680A (zh) * | 2011-05-03 | 2014-02-12 | 巴斯夫欧洲公司 | 二硫化物染料 |
CN103649077A (zh) * | 2011-06-29 | 2014-03-19 | 阿达梅德公司 | 用于治疗中枢神经***疾病的脂环族胺类的磺酰胺衍生物 |
CN104220421A (zh) * | 2012-03-20 | 2014-12-17 | 阿达梅德公司 | 用于治疗中枢神经***疾病的苄胺的磺酰胺衍生物 |
Non-Patent Citations (1)
Title |
---|
YA-LIN TU, 等: "Discovery of lipoic acid-4-phenyl-1H-pyrazole hybrids as novel bifunctional ROCK inhibitors with antioxidant activity", 《RSC ADVANCES》 * |
Also Published As
Publication number | Publication date |
---|---|
US10723724B2 (en) | 2020-07-28 |
CN106279136B (zh) | 2019-06-21 |
WO2018032666A1 (zh) | 2018-02-22 |
US20190202817A1 (en) | 2019-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110719902B (zh) | Ssao抑制剂 | |
CN103415519B (zh) | 作为β-分泌酶(BACE)抑制剂有用的6,7-二氢-吡唑[1,5-a]吡嗪-4-基胺衍生物 | |
CN108137562A (zh) | 吡唑嘧啶衍生物及其用途 | |
CN104066431B (zh) | 吡嗪激酶抑制剂 | |
CN102378762A (zh) | 丙型肝炎病毒抑制剂 | |
TW201213329A (en) | Pyrazine derivatives as ENaC blockers | |
CN107207524A (zh) | 双苄基异喹啉衍生物、其制备方法及其在肝病的治疗与预防中的用途 | |
CN106795152A (zh) | 蛋白激酶抑制剂 | |
JP2023554282A (ja) | 置換ピペリジノ化合物及び関連する治療方法 | |
CN116348468A (zh) | Cftr调节剂化合物、组合物及其用途 | |
CN106279136B (zh) | 治疗中枢神经***退行性疾病或脑肿瘤的化合物及其应用 | |
CN102617478B (zh) | 苯并咪唑、噁唑和噻唑衍生物的合成及其应用 | |
Salman et al. | New Gemcitabine Derivatives as potent in vitro α-Glucosidase Inhibitors | |
CN105949180B (zh) | 治疗中枢神经***退行性疾病的化合物及其应用 | |
WO2014086102A1 (zh) | 作为酪氨酸激酶抑制剂的吲哚满酮衍生物 | |
EP3447045B1 (en) | 1-(1-hydroxy-2,3-dihydro-1h-inden-5-yl)-urea derivatives and related compounds kcnq 2-5 channel activators for treating dysuria | |
CN114728917A (zh) | 草酰胺类衍生物、其制备方法及其在医药上的应用 | |
CN106459030B (zh) | 取代托品烷衍生物 | |
CA2883014A1 (en) | Derivatives of 1-(substituted sulfonyl)-2-aminoimidazoline as antitumor and antiproliferative agents | |
AU2018205277A1 (en) | Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) for the treatment of neurodegenerative diseases | |
CN101602750A (zh) | (取代)萘基、(取代)芳基、哌嗪基脒类化合物 | |
CN117836270A (zh) | Usp30抑制剂及其用途 | |
US20130345420A9 (en) | Selective inhibitors of excitatory amino acid transporter subtype 1 (eaat1/glast) | |
JPH0395166A (ja) | イソキサゾロン誘導体含有脳機能改善剤 | |
WO2023093787A1 (zh) | 苯并二氮杂䓬类化合物及其作为Rho激酶抑制剂的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |